Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC.
0/5 보강
APA
Xiang X, Yu Y (2026). Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC.. Liver international : official journal of the International Association for the Study of the Liver, 46(2), e70512. https://doi.org/10.1111/liv.70512
MLA
Xiang X, et al.. "Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC.." Liver international : official journal of the International Association for the Study of the Liver, vol. 46, no. 2, 2026, pp. e70512.
PMID
41510573
같은 제1저자의 인용 많은 논문 (5)
- The Treatment of Alar Base Depression in Rhinoplasty with Diced Autologous Cartilage or Mass Cartilage: A Systematic Review.
- Recent advances of engineered bacteria for therapeutic applications.
- Unique gut microbiota and metabolomic profiling as biomarker of post-transplant recovery in acute-on-chronic liver failure after liver transplantation.
- Emerging roles and therapeutic implications of lipid droplet protein perilipin 2 in liver disease.
- Comprehensive analysis of programmed cell death and oridonin target identification in primary lung cancer for prognostic prediction and therapeutic strategies.